S

Soleno Therapeutics

SLNO

49.320
USD
0.87
(1.80%)
Market Open
Volume
6,766
EPS
0
Div Yield
0
P/E
-30
Market Cap
2,100,620,940
Related Instruments
B
BNTC
-0.46000
(-5.34%)
8.15000 USD
G
GLMD
-0.00350
(-1.12%)
0.31000 USD
K
KALA
-0.29000
(-4.40%)
6.30000 USD
O
ONTX
0
(0%)
0.000000 USD
S
SINT
-0.26000
(-5.11%)
4.83000 USD
News

Title: Soleno Therapeutics

Sector: Healthcare
Industry: Biotechnology
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet forthe treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.